Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 3Completed 2Withdrawn 1Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 9INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 428Neoplasms 296Breast Neoplasms 296Colorectal Neoplasms 241Neoplasm Metastasis 196Ovarian Neoplasms 171Lung Neoplasms 149Recurrence 148Prostatic Neoplasms 146Pancreatic Neoplasms 141Multiple Myeloma 136Stomach Neoplasms 129Squamous Cell Carcinoma of Head and Neck 128Melanoma 123Leukemia, Myeloid, Acute 115Endometrial Neoplasms 114Advanced Solid Tumors 113Advanced Solid Tumor 108Carcinoma, Hepatocellular 102Triple Negative Breast Neoplasms 101Small Cell Lung Carcinoma 88Uterine Cervical Neoplasms 86Lymphoma, Non-Hodgkin 83Carcinoma, Renal Cell 72Lymphoma, Follicular 71Lymphoma 67Leukemia, Lymphocytic, Chronic, B-Cell 65Solid Tumor 64Lymphoma, Large B-Cell, Diffuse 64Hematologic Neoplasms 61

Interventions

belzutifan 2palbociclib 1lenvatinib 1cabozantinib 1Nivolumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × von Hippel-Lindau Disease × Clear all
NCT07405164 2026-05-29

MK-6482-043

Merck Sharp & Dohme LLC

Phase 3 Recruiting
450 enrolled
Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT04924075 2026-05-28

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
322 enrolled 1 FDA
CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT06553339 2024-08-14

A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Recruiting
60 enrolled

von Hippel-Lindau Disease, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡